Does the media refer more to BIOA or FULC?

In the previous week, BioAge Labs had 4 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 12 mentions for BioAge Labs and 8 mentions for Fulcrum Therapeutics. BioAge Labs' average media sentiment score of 0.35 beat Fulcrum Therapeutics' score of 0.09 indicating that BioAge Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Fulcrum Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is JBIO or FULC more profitable?

Fulcrum Therapeutics' return on equity of -28.54% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Jade Biosciences N/A -51.34% -47.32% Fulcrum Therapeutics N/A -28.54% -27.16%

Does the media prefer JBIO or FULC?

In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Jade Biosciences. MarketBeat recorded 8 mentions for Fulcrum Therapeutics and 4 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.16 beat Fulcrum Therapeutics' score of 0.09 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, IVA or FULC?

Fulcrum Therapeutics has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 174.12 -$400.67M N/A N/A Fulcrum Therapeutics $80M 3.09 -$74.88M -$1.15 N/A

Is IVA or FULC more profitable?

Inventiva's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Fulcrum Therapeutics N/A -28.54% -27.16%

Does the media favor IVA or FULC?

In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Inventiva. MarketBeat recorded 8 mentions for Fulcrum Therapeutics and 4 mentions for Inventiva. Inventiva's average media sentiment score of 0.66 beat Fulcrum Therapeutics' score of 0.09 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ANRO or FULC more profitable?

Fulcrum Therapeutics' return on equity of -28.54% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -47.22% -38.81% Fulcrum Therapeutics N/A -28.54% -27.16%

Does the media refer more to ANRO or FULC?

In the previous week, Fulcrum Therapeutics had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 8 mentions for Fulcrum Therapeutics and 7 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 1.41 beat Fulcrum Therapeutics' score of 0.09 indicating that Alto Neuroscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate FULC or VYNE?

Fulcrum Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 121.02%. Given Fulcrum Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Fulcrum Therapeutics is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 4 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 VYNE Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor FULC or VYNE?

In the previous week, Fulcrum Therapeutics had 6 more articles in the media than VYNE Therapeutics. MarketBeat recorded 8 mentions for Fulcrum Therapeutics and 2 mentions for VYNE Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.09 beat VYNE Therapeutics' score of -0.12 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VYNE Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Fulcrum Therapeutics (FULC) Competitors

$3.71 +0.13 (+3.63%)

Closing price 04:00 PM Eastern

Extended Trading

$3.68 -0.03 (-0.84%)

As of 07:38 PM Eastern

Compare

FULC vs. BIOA, JBIO, IVA, ANRO, and VYNE

Should you buy Fulcrum Therapeutics stock or one of its competitors? MarketBeat compares Fulcrum Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fulcrum Therapeutics include BioAge Labs (BIOA), Jade Biosciences (JBIO), Inventiva (IVA), Alto Neuroscience (ANRO), and VYNE Therapeutics (VYNE).

How does Fulcrum Therapeutics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 17.6% of BioAge Labs shares are owned by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Fulcrum Therapeutics has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	53.30	-$80.61M	-$2.40	N/A
Fulcrum Therapeutics	$80M	3.09	-$74.88M	-$1.15	N/A

Fulcrum Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. Fulcrum Therapeutics' return on equity of -28.54% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Fulcrum Therapeutics	N/A	-28.54%	-27.16%

In the previous week, BioAge Labs had 4 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 12 mentions for BioAge Labs and 8 mentions for Fulcrum Therapeutics. BioAge Labs' average media sentiment score of 0.35 beat Fulcrum Therapeutics' score of 0.09 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Fulcrum Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioAge Labs presently has a consensus price target of $36.57, indicating a potential upside of 239.25%. Fulcrum Therapeutics has a consensus price target of $8.20, indicating a potential upside of 121.02%. Given BioAge Labs' stronger consensus rating and higher possible upside, research analysts plainly believe BioAge Labs is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

BioAge Labs has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.05, meaning that its share price is 205% more volatile than the broader market.

Summary

Fulcrum Therapeutics beats BioAge Labs on 9 of the 16 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Jade Biosciences has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.05, meaning that its stock price is 205% more volatile than the broader market.

Jade Biosciences presently has a consensus price target of $51.57, indicating a potential upside of 169.30%. Fulcrum Therapeutics has a consensus price target of $8.20, indicating a potential upside of 121.02%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Jade Biosciences is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Fulcrum Therapeutics has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
Fulcrum Therapeutics	$80M	3.09	-$74.88M	-$1.15	N/A

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Jade Biosciences. MarketBeat recorded 8 mentions for Fulcrum Therapeutics and 4 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.16 beat Fulcrum Therapeutics' score of 0.09 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fulcrum Therapeutics' return on equity of -28.54% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Fulcrum Therapeutics	N/A	-28.54%	-27.16%

Summary

Fulcrum Therapeutics beats Jade Biosciences on 9 of the 15 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Inventiva?

Inventiva (NASDAQ:IVA) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Inventiva currently has a consensus target price of $16.56, suggesting a potential upside of 289.54%. Fulcrum Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 121.02%. Given Inventiva's stronger consensus rating and higher probable upside, research analysts plainly believe Inventiva is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Inventiva. MarketBeat recorded 8 mentions for Fulcrum Therapeutics and 4 mentions for Inventiva. Inventiva's average media sentiment score of 0.66 beat Fulcrum Therapeutics' score of 0.09 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inventiva's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Fulcrum Therapeutics	N/A	-28.54%	-27.16%

Fulcrum Therapeutics has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	174.12	-$400.67M	N/A	N/A
Fulcrum Therapeutics	$80M	3.09	-$74.88M	-$1.15	N/A

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Inventiva has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.05, suggesting that its stock price is 205% more volatile than the broader market.

Summary

Inventiva beats Fulcrum Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

In the previous week, Fulcrum Therapeutics had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 8 mentions for Fulcrum Therapeutics and 7 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 1.41 beat Fulcrum Therapeutics' score of 0.09 indicating that Alto Neuroscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fulcrum Therapeutics' return on equity of -28.54% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Fulcrum Therapeutics	N/A	-28.54%	-27.16%

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alto Neuroscience has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.05, indicating that its stock price is 205% more volatile than the broader market.

Alto Neuroscience presently has a consensus price target of $35.25, indicating a potential upside of 29.14%. Fulcrum Therapeutics has a consensus price target of $8.20, indicating a potential upside of 121.02%. Given Fulcrum Therapeutics' higher probable upside, analysts clearly believe Fulcrum Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Alto Neuroscience has higher earnings, but lower revenue than Fulcrum Therapeutics. Alto Neuroscience is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Fulcrum Therapeutics	$80M	3.09	-$74.88M	-$1.15	N/A

Summary

Fulcrum Therapeutics beats Alto Neuroscience on 9 of the 14 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to VYNE Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Fulcrum Therapeutics has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. Fulcrum Therapeutics' return on equity of -28.54% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-28.54%	-27.16%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

Fulcrum Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 121.02%. Given Fulcrum Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Fulcrum Therapeutics is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
VYNE Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

VYNE Therapeutics has lower revenue, but higher earnings than Fulcrum Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.09	-$74.88M	-$1.15	N/A
VYNE Therapeutics	$570K	33.29	-$26.48M	-$0.38	N/A

Fulcrum Therapeutics has a beta of 3.05, meaning that its share price is 205% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, meaning that its share price is 100% more volatile than the broader market.

In the previous week, Fulcrum Therapeutics had 6 more articles in the media than VYNE Therapeutics. MarketBeat recorded 8 mentions for Fulcrum Therapeutics and 2 mentions for VYNE Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.09 beat VYNE Therapeutics' score of -0.12 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fulcrum Therapeutics beats VYNE Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Fulcrum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FULC vs. The Competition

Export

Metric	Fulcrum Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$238.55M	$3.55B	$6.86B	$12.45B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-3.23	7.29	280.72	24.99
Price / Sales	3.09	1,264.07	588.04	90.94
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	0.58	16.89	11.02	6.21
Net Income	-$74.88M	-$12.54M	$3.48B	$347.49M
7 Day Performance	-0.54%	-0.63%	0.56%	0.89%
1 Month Performance	-3.39%	-7.41%	-4.14%	-3.60%
1 Year Performance	-45.68%	49.17%	63.23%	20.46%

Fulcrum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FULC Fulcrum Therapeutics	3.4585 of 5 stars	$3.71 +3.6%	$8.20 +121.0%	-47.6%	$238.55M	$80M	N/A	100	Earnings Report Upcoming Earnings
BIOA BioAge Labs	3.1855 of 5 stars	$21.92 +5.0%	$43.50 +98.4%	+119.4%	$974.34M	$8.99M	N/A	N/A	News Coverage Analyst Forecast Short Interest Decrease Gap Up
JBIO Jade Biosciences	3.2626 of 5 stars	$19.70 -1.3%	$51.57 +161.8%	+186.6%	$972.39M	N/A	N/A	20	News Coverage Positive News
IVA Inventiva	2.7702 of 5 stars	$4.64 +0.9%	$16.56 +256.8%	+39.1%	$963.76M	$4.48M	N/A	100	Gap Down
ANRO Alto Neuroscience	2.4146 of 5 stars	$27.40 -1.7%	$35.25 +28.6%	+785.5%	$961.47M	N/A	N/A	N/A	News Coverage Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FULC) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulcrum Therapeutics (FULC) Competitors

FULC vs. BIOA, JBIO, IVA, ANRO, and VYNE

How does Fulcrum Therapeutics compare to BioAge Labs?

Summary

How does Fulcrum Therapeutics compare to Jade Biosciences?

Summary

How does Fulcrum Therapeutics compare to Inventiva?

Summary

How does Fulcrum Therapeutics compare to Alto Neuroscience?

Summary

How does Fulcrum Therapeutics compare to VYNE Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulcrum Therapeutics (FULC) Competitors

FULC vs. BIOA, JBIO, IVA, ANRO, and VYNE

How does Fulcrum Therapeutics compare to BioAge Labs?

Do insiders and institutionals have more ownership in BIOA or FULC?

Which has stronger valuation and earnings, BIOA or FULC?

Is BIOA or FULC more profitable?

Does the media refer more to BIOA or FULC?

Do analysts recommend BIOA or FULC?

Which has more volatility & risk, BIOA or FULC?

Summary

How does Fulcrum Therapeutics compare to Jade Biosciences?

Which has more risk & volatility, JBIO or FULC?

Do analysts recommend JBIO or FULC?

Which has higher valuation & earnings, JBIO or FULC?

Do institutionals and insiders have more ownership in JBIO or FULC?

Does the media prefer JBIO or FULC?

Is JBIO or FULC more profitable?

Summary

How does Fulcrum Therapeutics compare to Inventiva?

Do analysts recommend IVA or FULC?

Does the media favor IVA or FULC?

Is IVA or FULC more profitable?

Which has better valuation and earnings, IVA or FULC?

Do insiders and institutionals hold more shares of IVA or FULC?

Which has more volatility & risk, IVA or FULC?

Summary

How does Fulcrum Therapeutics compare to Alto Neuroscience?

Does the media refer more to ANRO or FULC?

Is ANRO or FULC more profitable?

Do insiders & institutionals have more ownership in ANRO or FULC?

Which has more volatility & risk, ANRO or FULC?

Do analysts rate ANRO or FULC?

Which has preferable valuation & earnings, ANRO or FULC?

Summary

How does Fulcrum Therapeutics compare to VYNE Therapeutics?

Is FULC or VYNE more profitable?

Do analysts rate FULC or VYNE?

Do institutionals and insiders believe in FULC or VYNE?

Which has higher earnings & valuation, FULC or VYNE?

Which has more volatility & risk, FULC or VYNE?

Does the media favor FULC or VYNE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools